Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Etentamig · ABBV-383, TNB-383B

Bispecific antibody · Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 · developed by AbbVie

Phase 1/2 Most advanced trial
ABBV Developer
2 Registered trials

What is Etentamig?

Etentamig is a T-cell engaging bispecific IgG4 monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on cytotoxic T-lymphocytes. By redirecting these T-cells to BCMA-expressing tumor cells, it induces their killing. It is studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ABBV-383, TNB-383B
Drug type
Bispecific antibody
Targets
B-cell maturation antigen (TNFRSF17), CD3
Mechanism
Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3
Pathways
CTL-mediated tumor cell killing, plasma cell survival
Therapy area
Oncology
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
CO86AOP337

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07728188 Phase 3 Relapsed or Refractory Multiple Myeloma Recruiting ABBV
NCT05650632 Phase 1 Multiple Myeloma Recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

Other drugs acting on TNFRSF17

More from AbbVie

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Etentamig

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.